Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back
Abstract Session

Systemic lupus erythematosus (SLE)
General Topic: Clinical Science

12S148: Abstracts: SLE – Treatment I: Renal (0781–0786)

Sunday, November 12, 2023
2:00 PM – 3:30 PM PT
Location: Ballroom 20D

On Demand In Person

    Presenting Author(s)

  • AA

    Anna Arar, MS, BS

    Medical University of South Carolina
    Charleston, SC, United States

    Disclosure information not submitted.

  • Maria Dall'Era, MD (she/her/hers)

    Director
    UCSF
    Corte Madera, CA, United States

    Disclosure(s): Annexon Biosciences: Consultant (Ongoing), Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Aurinia: Consultant (Ongoing); Biogen: Consultant (Ongoing); GlaxoSmithKlein: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing)

  • SG

    Shivani Garg, MD, MS

    University of Madison, School of Medicine and Public Health
    Madison, WI, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

  • Brad Rovin, MD

    The Ohio State University
    Columbus, OH, United States

    Disclosure(s): AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Aurinia: Consultant (Ongoing), Grant/Research Support (Ongoing); Biogen: Consultant (Ongoing); F. Hoffmann-La Roche Ltd: Consultant (Ongoing); Genentech: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Novartis: Consultant (Ongoing)

  • AS

    Amit Saxena, MD

    NYU School of Medicine
    New York, NY, United States

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Terminated, March 15, 2023); AstraZeneca: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Terminated, December 8, 2021)

  • JT

    Jule Taubmann, MD, BSc

    Universitätsklinikum Erlangen
    Erlangen, Germany

    Disclosure information not submitted.

Abstract oral session.

Non-CME

Presentations:

  • 2:00 PM – 2:10 PM PT
    Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials

    Presenting Author: Amit Saxena, MD – NYU School of Medicine

  • 2:10 PM – 2:15 PM PT
    Q&A
  • 2:15 PM – 2:25 PM PT
    Comparison of Dual-immunosuppressive Therapy with a Voclosporin-based, Triple-immunosuppressive Regimen for Lupus Nephritis in the ALMS and AURORA 1 Studies

    Presenting Author: Maria Dall'Era, MD (she/her/hers) – UCSF

  • 2:25 PM – 2:30 PM PT
    Q&A
  • 2:30 PM – 2:40 PM PT
    Tolerability of CAR T Cell Therapy in Autoimmune Disease

    Presenting Author: Jule Taubmann, MD, BSc – Universitätsklinikum Erlangen

  • 2:40 PM – 2:45 PM PT
    Q&A
  • 2:45 PM – 2:55 PM PT
    Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial

    Presenting Author: Brad Rovin, MD – The Ohio State University

  • 2:55 PM – 3:00 PM PT
    Q&A
  • 3:00 PM – 3:10 PM PT
    Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity

    Presenting Author: Shivani Garg, MD, MS – University of Madison, School of Medicine and Public Health

  • 3:10 PM – 3:15 PM PT
    Q&A
  • 3:15 PM – 3:25 PM PT
    A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort

    Presenting Author: Anna Arar, MS, BS – Medical University of South Carolina

  • 3:25 PM – 3:30 PM PT
    Q&A